Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Hem/Onc > Chemotherapy > Flashcards

Chemotherapy Flashcards

1
Q

Bendamustine

A

Alkylating Agent
Treanda®, Bendeka®, Belrapzo®
CLL, indolent lymphomas (Hodgkins/NHL)
90 mg/m2 days 1 and 2 every 28 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Altretamine

A

Alkylating Agent
Hexalen capsules
Ovarian Cancer
removed from market

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Busulfan

A

Alkylating Agent

Busulfex® (16mg/kg) in combination with cyclophosphamide (120mg/kg) as a conditioning regimen prior to bone marrow or peripheral blood progenitor cell replacement for CML (BuCy)

Myleran® (PO) the palliative treatment of CML. 4-8 mg daily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Carboplatin

A

Alkylating Agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Carmustine

A

Alkylating Agent
BicNu (IV) or Gliadel wafer

150 to 200 mg/m2 intravenously every 6 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Chlorambucil

A

Alkylating Agent
Leukeran (po)
CLL, Hodgkin’s and NH lymphomas

0.1 to 0.2 mg/kg/day as palliative treatment (not for curative intent)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cisplatin

A

Curative Intent

Nephrotoxicity- hydration
Highly emetogenic
Ototoxicity
Accumulative Neuropathy

Metastatic Testicular cancer- 20 mg/m2
Metastatic Ovarian Cancer-
75 mg/m2 + cyclophosphamide
Bladder Cancer- 50-70 mg/m2
Broad Spectrum- many other uses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cyclophosphamide

A

Alkylating Agent

1 mg/kg to 5 mg/kg ONCE DAILY

HYDRATION to prevent renal toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Dacarbazine

A

Alkylating Agent
DTIC (IV)

metastatic malignant melanoma: 2-4.5 mg/kg/day x10 days every 4 weeks

Hodgkin’s disease:
150 mg/m2 x5 days every 4 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Ifosfamide

A

Alkylating Agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Lomustine

A

Alkylating Agent- Nitrosourea

Gleostine

Brain tumors
130 mg/m2 every 6 weeks

Hodgkins Lymphoma
80-100 mg/m2 in combination with chemo regimens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Mechlorethamine

A

Alkylating Agent
Original Nitrogen Mustard
Valchlor
mycosis fungoides-type cutaneous T-cell lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Melphalan

A

Alkylating Agent

Alkeran® tablets or IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Oxaliplatin

A

Alkylating Agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Temozolomide

A

Alkylating Agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Thiotepa

A

Alkylating Agent
Thioplex®, TSPA

Adenocarcinoma of the Breast or Ovary: 0.3 - 0.4 mg/kg every 1-4 weeks

Malignant Effusions: 0.6 to 0.8 mg/kg intracavitary q 1-4 weeks

Superficial Papillary Carcinoma of the Urinary Bladder: 60 mg intravesicularly once weekly x4 weeks

TEPADINA- peds with beta thalassemia (with BuCy prior to SCT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Trabectedin

A

Alkylating Agent
YONDELIS
liposarcoma or leiomyosarcoma

1.5 mg/m2 administered as an intravenous infusion over 24 hours through a central venous line every 21 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Streptozocin

A

Nitrosourea
Zanosar® (IV)
Treatment of islet cell cancer of the pancreas

500 mg/m2 daily x5 days every 6 weeks
or
1000 mg/m2 weekly then escalated

RENAL TOXICITY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Azacitidine

A

Hypomethylating Agent (HMA)

MDS: 75 mg/m2 SQ or IV daily x7 days every 28 days

AML: Onureg (po) 300 mg daily on Days 1 through 14 of each 28-day cycle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

5-fluorouracil (5-FU)

A

Antimetabolite

Indications: GI / Pancreatic / Breast

Bolus: false RNA base pair-neutropenia

Infusion: inhibits thymidylate synthase epithelial (hand foot / diarrhea)

Leucovorin: ^ thym synth inhibition

DPD deficiency

FOLFOX / FOLFIRINOX +- bevacizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

6-mercaptopurine (6-MP)

A

Antimetabolite

ALL- part of combination chemotherapy maintenance regimen

1.5 mg/kg to 2.5 mg/kg orally once daily

TPMT and NUDT15 Deficiency - dose adjustments

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Capecitabine

A

Antimetabolite

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Cladribine

A

Pur Ole Hairy Leu
Antimetabolite- Purine Analogue
Leustatin (IV)
Hairy Cell Leukemia

continuous infusion for 7 consecutive days at a dose of 0.09 mg/kg/day.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Clofarabine

A

Antimetabolite
Purine Analogue
Clolar (IV)

pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia (ALL)

52 mg/m2 as an intravenous infusion over 2 hours daily for 5 consecutive days of a 28-day cycle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Cytarabine
Antimetabolite Ara-C Pyrimidine Analogue Leukemias/Lymphomas 7 + 3 AML induction HDAC AML consolidation Hyper CVAD FLAG-Ida
26
Decitabine
Hypomethylating Agent (inhibits DNA methyltransferase) Dacogen, INQOVI (with cedazuridine) MDS 20 mg/m2 daily x5 days every 28 days
27
Floxuridine
Antimetabolite Pyrimidine Analogue FUDR (IV) continuous regional intra-arterial infusion (hepatic) palliative management of gastrointestinal adenocarcinoma metastatic to the liver
28
Fludarabine
Antimetabolite Purine Analogue Fludara (IV) CLL (FCR) 25 mg/m2 x5 days every 28 day cycle
29
Gemcitabine
Gemzar (IV) Ara-C of solid tumors Breast gem (1250 mg/m²) + paclitaxel Ovarian gem (1000)+ carboplatin Pancreas- single agent (1000 mg/m²) NSLC- gem (1000 mg/m²)+ cisplatin
30
Methotrexate
Antimetabolite
31
Nelarabine
Antimetabolite Purine Analogue Arronon (IV) T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
32
Pemetrexed
Antimetabolite (anti-folate) Alimta Indications: NSCLC In combination with pembrolizumab and a platinum containing therapy 500 mg/m2 every 21 day cycle Short 10 min infusion- very well tolerated Billion dollar subgroup analysis- Skagliatti paper- pref for adenocarcinoma
33
Pentostatin
Antimetabolite Purine Analogue Nipent (IV) Hairy cell leukemia (single-agent) 4 mg/m2 every other week
34
Thioguanine
Antimetabolite 6-TG Tabloid (po) 40 mg tablets Indications: AML ALL
35
Trifluridine/tipiracil
Antimetabolite Pyrimidine analogue Lonsurf (po)
36
Pralatrexate
Antimetabolite- dihydrofolate reductase inhibitor Folotyn (IV) Indications: peripheral T-cell Lymphoma (PTCL) 30 mg/m2 weekly 6 weeks every 7 week cycle
37
Hydroxyurea
Antimetabolite Inhibits ribonucleotide reductase (RR) Which halts synthesis of DNA Myeloproliferative Neoplasms Essential Thrombocythemia, Polycythemia Vera CML For Sickle Cell-> increases fetal Hgb
38
Daunorubicin
Anthracycline Cerubidine® AML, APL, ALL 7+3 daunorubicin 45 mg/m2 IV on d 1, 2, and 3 and cytarabine 100 mg/m2/day x7 days
39
Doxorubicin
Anthracycline Adriamycin Doxorubicin Liposomal
40
Epirubicin
Anthracycline EllenceTM AC Breast Cancer
41
Idarubicin
Anthracycline Induction therapy for AML 12 mg/m2 daily for 3 days in combination with cytarabine 100 mg/m2 daily for 7 days (7 + 3 regimen) FLAG-IDA
42
Valrubicin
Anthracycline Valstar ® INTRAVESICAL therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder 800 mg administered intravesically once a week for six weeks
43
Bleomycin
Anti-tumor Antibiotic Blenoxane® Hodgkins Lymphoma- ABVD Testicular/Ovarian Cancer- BEP Malignant Pleural Effusions NO myelosuppression PULM TOXICITY- Pulmonary Fibrosis
44
Dactinomycin
Anti-tumor Antibiotic Cosmegen® Wilms Tumor / Rhabdomyosarcoma Ewing Sarcoma / Metastatic Nonseminomatous Testicular Cancer
45
Mitomycin-C
Anti-tumor Antibiotic MTC Vesicant** IV or Intravesicularly (into the bladder)
46
Mitoxantrone
Novantrone ® (Other Name: DHAD) Anti-tumor Antibiotic Topoisomerase II Inhibitor Hormone-Refractory Prostate Cancer 12 to 14 mg/m2 every 21 days + steroids Initial Therapy for ANLL (ie AML) 12 mg/m2 + cytarabine CARDIOTOXICITY
47
Irinotecan
Topoisomerase I Inhibitor Camptosar Irinotecan liposomal (Onivyde) + 5FU/LV for pancreatic cancer
48
Topotecan
Topoisomerase I Inhibitor Hycamtin® (PO or IV) 1 mg or 0.25 mg CAPSULES ONLY indicated for Small Cell Lung Cancer 2.3 mg/m2/day PO daily x5 days every 21 day cycle Ovarian Cancer and Small Cell Lung Cancer: 1.5 mg/m2 IV daily x5 days every 21 day cycle Cervical Cancer: 0.75 mg/m2 IV on Days 1, 2, and 3, with cisplatin 50 mg/m2 on Day 1, of a 21-day cycle
49
Etoposide
Topoisomerase II Inhibitor VePesid capsules / VP-16 Refractory Testicular Tumors (BEP)- IV 50 to 100 mg/m 2/day on days 1 through 5 Small Cell Lung Cancer- IV or PO 35 mg/m 2/day for 4 days to 50 mg/m 2/day for 5 days dose of CAPSULES is 2x the IV dose rounded to the nearest 50 mg R-ICE for lymphomas
50
Teniposide
Topoisomerase II Inhibitor Vumon® VM-26 Induction therapy in childhood ALL
51
Cabazitaxel
Taxane- Microtubule (mitotic) Inhibitor Jevtana® castrate resistant metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
52
Docetaxel
Taxane- Microtubule (mitotic) Inhibitor
53
Nab-paclitaxel
Taxane- Microtubule (mitotic) Inhibitor
54
Paclitaxel
Taxane- Microtubule (mitotic) Inhibitor
55
Vinblastine
Vinca Alkaloid- microtubule inhibitor
56
Vincristine
Vinca Alkaloid- microtubule inhibitor (M Phase specific) Oncovin® Lymphomas/Leukemias NO bone marrow suppression Peripheral neuropathy R-CHOP, hyper-CVAD, EPOCH
57
Vincristine liposomal
Vinca Alkaloid- microtubule inhibitor
58
Vinorelbine
Vinca Alkaloid- microtubule inhibitor Navelbine® first-line treatment of patients with locally advanced or metastatic NSCLC 25 mg/m2 weekly + cisplatin 100 mg/m2 q 4 weeks 30 mg/m2 weekly + cisplatin 120 mg/m2 q 6 weeks 30 mg/m2 single agent
59
Tretinoin
Vitamin A derivative Vesanoid, ATRA Acute Promyelocytic Leukemia (APL) induces cytodifferentiation and decreased proliferation of APL cells
60
Arsenic trioxide
Trisenox (ATO) DNA fragmentation and degradation of PML/RAR protein acute promyelocytic leukemia (APL) w/ the presence of the t(15;17) translocation or PML/RAR-alpha
61
Asparaginase
Enzyme that breaks down aspargine Oncaspar (pegylated) IM or IV ALL
62
Gemtuzumab ozogamicin
Mylotarg® Antibody Drug Conjugate (ADC) CD-33 AML

Hem/Onc (16 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions